Who Exports Carvedilol from India — 242 Suppliers Behind a $98.1M Market
India's carvedilol export market is supplied by 242 active exporters who collectively shipped $98.1M across 4,750 shipments. ZYDUS LIFESCIENCES LIMITED leads with a 22.3% market share, followed by CARITAS HEALTHCARE PRIVATE LIMITED and PIRAMAL PHARMA LIMITED. The top 5 suppliers together control 64.0% of total export value, reflecting a concentrated market structure.
Top Carvedilol Exporters from India — Ranked by Export Value
ZYDUS LIFESCIENCES LIMITED is the leading carvedilol exporter from India, holding a 22.3% share of the $98.1M market across 4,750 shipments from 242 exporters. The top 5 suppliers — ZYDUS LIFESCIENCES LIMITED, CARITAS HEALTHCARE PRIVATE LIMITED, PIRAMAL PHARMA LIMITED, GLENMARK PHARMACEUTICALS LIMITED, AUROBINDO PHARMA LTD — collectively control 64.0% of total export value, indicating a moderately concentrated market. Individual shares are: ZYDUS LIFESCIENCES LIMITED (22.3%), CARITAS HEALTHCARE PRIVATE LIMITED (16.4%), PIRAMAL PHARMA LIMITED (9.0%), GLENMARK PHARMACEUTICALS LIMITED (8.6%), AUROBINDO PHARMA LTD (7.8%).
Top Carvedilol Exporters from India
Ranked by export value · 242 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | ZYDUS LIFESCIENCES LIMITED CARVEDILOL TAB 25MG 500CARVEDILOL TABLETS 6.25MG 500CARVEDILOL TABLETS 25MG 500S | $21.9M | 4 | 22.3% |
| 2 | CARITAS HEALTHCARE PRIVATE LIMITED CARVEDILOL TABLETS 12.5MGFINISHED PHARAMCEUTICAL PRODUCT - CARVEDILOL TABLETS 12.5MGCARVEDILOL TABLETS USP 12.5MG | $16.1M | 1 | 16.4% |
| 3 | PIRAMAL PHARMA LIMITED CARVEDILOL TAB 25MG 500CARVEDILOL TABLETS 6.25MG 500CARVEDILOL TABLETS 25MG 500S | $8.8M | 1 | 9.0% |
| 4 | GLENMARK PHARMACEUTICALS LIMITED CARVEDILOL TAB 25MG 500CARVEDILOL TABLETS 6.25MG 500CARVEDILOL TABLETS 25MG 500S | $8.4M | 2 | 8.6% |
| 5 | AUROBINDO PHARMA LTD CARVEDILOL TAB 25MG 500CARVEDILOL TABLETS 6.250MG(CARVEDILOL 6.CARVEDILOL TABLETS 12.5MG(CARVEDILOL 12. | $7.6M | 15 | 7.8% |
| 6 | CIPLA LIMITED CARLOC 6.25 TABLETCARVEDILOL 12.5 MG TABLET DOCUMENTCARVEDILOL 12.5MG TABLETS | $6.9M | 4 | 7.0% |
| 7 | RUBICON RESEARCH PRIVATE LIMITED CARVEDILOL TAB 25MG 500CARVEDILOL TABLETS 6.25MG 500CARVEDILOL TABLETS 25MG 500S | $6.6M | 1 | 6.7% |
| 8 | CADILA HEALTHCARE LIMITED CARVEDILOL TAB 25MG 500CARVEDILOL TABLETS 6.25MG 500CARVEDILOL TABLETS 25MG 500S | $3.0M | 2 | 3.1% |
| 9 | AUROBINDO PHARMA LIMITED CARVEDILOL TAB 25MG 500CARVEDILOL TABLETS 6.250MG(CARVEDILOL 6.CARVEDILOL TABLETS 12.5MG(CARVEDILOL 12. | $2.0M | 12 | 2.1% |
| 10 | RUBICON RESEARCH LIMITED CARVEDILOL TAB 25MG 500CARVEDILOL TABLETS 6.25MG 500CARVEDILOL TABLETS 25MG 500S | $2.0M | 1 | 2.1% |
| 11 | CADILA HEALTHCARE LTD CARVEDILOL TAB 25MG 500CARVEDILOL TABLETS 6.25MG 500CARVEDILOL TABLETS 25MG 500S | $1.9M | 2 | 1.9% |
| 12 | SANDOZ PRIVATE LIMITED CARVEDILOL TAB 25MG 500CARVEDILOL TABLETS 6.25MG 500CARVEDILOL TABLETS 25MG 500S | $1.5M | 2 | 1.5% |
| 13 | TORRENT PHARMACEUTICALS LTD PHARMACEUTICAL PRODUCTS HARMLESS MEDICINE, CARVESAPH -25CARVEDILOL TABLETS 6.250MG(CARVEDILOL 6.CARVEDILOL TABLETS 12.5MG(CARVEDILOL 12. | $1.1M | 10 | 1.1% |
| 14 | BDH INDUSTRIES LIMITED PHARMACEUTICAL PRODUCTS HARMLESS MEDICINE, CARVESAPH -25PHARMACEUTICAL PRODUCTS HARMLESS MEDICINE, CARVESAPH -12.5CARVEDILOL 25 MG TABLETS KARVIDOL | $825.8K | 1 | 0.8% |
| 15 | AMNEAL PHARMACEUTICALS PRIVATE LIMITED CARVEDILOL TAB 25MG 500CARVEDILOL TABLETS 6.25MG 500CARVEDILOL TABLETS 25MG 500S | $812.6K | 1 | 0.8% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Carvedilol exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Zydus Lifesciences Limited | Approved | Yes | Yes | 80+ | Zydus offers over 80 FDA-approved generic products across various therapeutic ca |
| Glenmark Pharmaceuticals Limited | Approved | Yes | Yes | Not specified | Glenmark received an FDA warning letter in July 2025 for its Madhya Pradesh faci |
| Aurobindo Pharma Limited | Approved | Yes | Yes | Not specified | Aurobindo received an FDA warning letter in June 2019 for its Pydibhimavaram fac |
| Cadila Pharmaceuticals Limited | Approved | Yes | Yes | Not specified | Cadila Pharmaceuticals received an FDA warning in March 2014 for its Ankleshwar |
TransData Nexus reviewed the regulatory standing of 4 leading Carvedilol exporters from India. 4 hold US FDA facility approvals, 4 maintain WHO-GMP certification, and 4 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Carvedilol sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for Active Pharmaceutical Ingredient (API) production. The region's infrastructure supports large-scale manufacturing, making it a key player in the production of APIs like Carvedilol. Companies such as Aurobindo Pharma Ltd., which contributed $7.6 million (7.8%) to Carvedilol exports, have significant operations in this cluster.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. This cluster hosts companies like Zydus Lifesciences Limited, the leading exporter of Carvedilol with $21.9 million (22.3%) in exports, and Piramal Pharma Limited, contributing $8.8 million (9.0%). The region's emphasis on finished dosage forms complements the API production from other clusters, facilitating a comprehensive supply chain for Carvedilol.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad region serves as a critical export gateway due to its proximity to major ports and well-established logistics infrastructure. Companies like Glenmark Pharmaceuticals Limited, with $8.4 million (8.6%) in Carvedilol exports, leverage this strategic location to efficiently distribute products to international markets. The region's connectivity enhances the competitiveness of Indian pharmaceutical exports.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, partly due to favorable tax incentives. This cluster attracts numerous pharmaceutical companies, contributing to the diversified production landscape of drugs like Carvedilol.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Evaluate Supplier Capabilities: Assess the manufacturing capabilities and compliance records of suppliers, especially those in the top exporting clusters, to ensure consistent quality and supply.
- Leverage Export Data: Utilize detailed export data to identify emerging suppliers and market trends, enabling informed sourcing decisions.
- Monitor Regulatory Compliance: Ensure that suppliers adhere to international regulatory standards, particularly when exporting to highly regulated markets like the United States, which accounted for 60.1% of Carvedilol exports.
By strategically sourcing from India's diverse pharmaceutical clusters and maintaining rigorous supplier evaluation processes, companies can optimize their supply chains for Carvedilol and other pharmaceutical products.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Carvedilol exporters from India
Aurobindo Pharma Ltd — Aurobindo Pharma recalls Cinacalcet tablets in the US
Aurobindo Pharma USA Inc., a subsidiary of Aurobindo Pharma Ltd, initiated a recall of over 100,000 bottles of Cinacalcet tablets due to the presence of N-nitroso Cinacalcet impurity above the FDA's recommended interim limit. - IMPACT: This recall may affect Aurobindo's reputation and could lead to increased scrutiny of its manufacturing processes, potentially impacting its Carvedilol exports.
Impact: This recall may affect Aurobindo's reputation and could lead to increased scrutiny of its manufacturing processes, potentially impacting its Carvedilol exports.
Common Questions — Carvedilol Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which carvedilol supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, ZYDUS LIFESCIENCES LIMITED leads with 656 recorded shipments worth $21.9M. CARITAS HEALTHCARE PRIVATE LIMITED (29 shipments) and PIRAMAL PHARMA LIMITED (141 shipments) are also established high-volume exporters.
Q How many carvedilol manufacturers are there in India?
India has 242 active carvedilol exporters with a combined export market of $98.1M across 4,750 shipments to 98 countries. The top 5 suppliers hold 64.0% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for carvedilol from India?
Average FOB unit price: $2.12 per unit, ranging from $0.00 to $246.85. Average shipment value: $20.6K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 242 verified Indian exporters of Carvedilol ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 4,750 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 98 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
4,750 Verified Shipments
242 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists